Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cyclothiazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | GRIA1 | P42261 | 1/20 | 1.00 |
| ▸ | GRIA2 | P42262 | 1/20 | 1.00 |
| ▸ | GRIA3 | P42263 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | GRIA4 | P48058 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclothiazide SCHEMBL121096 | 1.00 | LMNA (1.00) | LMNACYP3A4KMT2ATHRBCHRM1 | |
| Cyclothiazide SCHEMBL22823942 | 1.00 | LMNA (1.00) | LMNACYP3A4KMT2ATHRBCHRM1 | |
| SCHEMBL22824000 | 0.96 | LMNA (0.92) | LMNACYP3A4KMT2ATHRBCHRM1 | |
| Cyclothiazide SCHEMBL21587525 | 0.92 | LMNA (0.85) | LMNACYP3A4KMT2ATHRBCHRM1 | |
| Cyclothiazide SCHEMBL28279779 | 0.89 | LMNA (0.78) | LMNACYP3A4KMT2ATHRBCHRM1 | |
| Cyclothiazide SCHEMBL28086726 | 0.87 | LMNA (0.76) | LMNACYP3A4KMT2ATHRBCHRM1 | |
| Cyclothiazide SCHEMBL28086372 | 0.87 | LMNA (0.76) | LMNACYP3A4KMT2ATHRBCHRM1 | |
| SCHEMBL17471612 | 0.87 | LMNA (0.76) | LMNACYP3A4KMT2ATHRBCHRM1 | |
| Cyclothiazide SCHEMBL7614349 | 0.86 | LMNA (0.73) | LMNACYP3A4KMT2ATHRBCHRM1 | |
| SCHEMBL19166751 | 0.84 | LMNA (0.73) | LMNACYP3A4KMT2ATHRBCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110366414-A | Composition for treating hypertension | 乔治全球健康研究院 | 2019-10-22 | — | — | CN | claimed |
| CN-108348469-A | Therapeutic compositions | 德马克有限责任公司 | 2018-07-31 | — | — | CN | claimed |
| CN-107261144-A | Treat the new treatment of Alzheimer disease | 法奈科斯公司 | 2017-10-20 | — | — | CN | claimed |
| CN-106715473-A | Antibodies to ticagrelor and methods of use thereof | 免疫医疗有限公司 | 2017-05-24 | — | — | CN | claimed |
| CN-105556305-A | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | ASTUTE MEDICAL INC | 2016-05-04 | — | — | CN | claimed |
| CN-103245724-B | The detection method of neurocyte discharge performance under Variable Composition drug effect | SOUTHEAST UNIVERSITY (CN) | 2015-10-07 | — | — | CN | claimed |
| WO-2013159166-A1 | PHARMACEUTICAL ORAL DOSAGE FORM FOR PREVENTING VASCULAR DISEASES, TABLET AS PHARMACEUTICAL DOSAGE FORM AND GELATIN CAPSULE AS PHARMACEUTICAL DOSAGE FORM | HYPERMARCAS S.A. (BR) | 2013-10-31 | — | — | WO | claimed |
| CN-103245724-A | Nerve cell discharge performance detection method under variable concentration medicine action | UNIV SOUTHEAST | 2013-08-14 | — | — | CN | claimed |
| WO-2008037224-A2 | CONTROLLED RELEASE DOSAGE FORM CONTAINING LERCANIDIPINE AND A PERFORMANCE ENHANCING ACID | OSMOTICA CORP. (VG) | 2008-04-03 | — | — | WO | claimed |
| CN-1227029-C | Combination of hypertensin converting enzyme inhibitor with a diuretic for treating microcirculation disorders | SERVIER LAB (FR) | 2005-11-16 | — | — | CN | claimed |
| CN-1315945-A | Nitrate salts of antihypertensive drugs | NICOX SA (FR) | 2001-10-03 | — | — | CN | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| CN-1279615-A | Use of a combination of a invertase inhibitor and a diuretic for the treatment of microcirculation disorders | ADIR (FR) | 2001-01-10 | — | — | CN | claimed |
| EP-3565808-B1 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-12281103-B2 | Compounds useful for treating gastrointestinal tract disorders | ARDELYX, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-5668117-A | NERVOUS SYSTEM DISORDERS USING AROMATIC ACID COMPOUNDS | SECANT PHARMA, LLC | 1997-09-16 | — | — | US | disclosed |
| US-5612225-A | COMBUSTION OF SAMPLE IN OXYGEN, REDUCING THE COMBUSTION GASES BY FLOWING CARRIER GAS, DRYING AND ANALYZING | FISONS INSTRUMENTS S.P.A. (IT) | 1997-03-18 | — | — | US | disclosed |
| EP-0586969-A2 | Process and apparatus for determining total nitrogen content by elemental analysis | FISONS INSTRUMENTS S.p.A. (IT) | 1994-03-16 | — | — | EP | disclosed |
| US-4019864-A | Method for measuring radioactivities of tritium and carbon-14 in sample air and apparatus for performing the same method | SAGAMI CHEMICAL RESEARCH CENTER (JA) | 1977-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281103-B2 | Compounds useful for treating gastrointestinal tract disorders | SLC10A2, FABP2, SLC10A1 | LMNA 4122/4885CYP3A4 2966/4885KMT2A 4033/4885 |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | LMNA 3715/4885CYP3A4 3251/4885KMT2A 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.